Photo from wikipedia
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u‐HCC) patients classified as Child‐Pugh A (CP‐A). This study aimed to elucidate the prognosis of patients treated with Atez/Bev, especially… Click to show full abstract
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u‐HCC) patients classified as Child‐Pugh A (CP‐A). This study aimed to elucidate the prognosis of patients treated with Atez/Bev, especially CP‐A and ‐B cases.
Keywords:
plus bevacizumab;
child pugh;
atezolizumab plus;
treatment;
therapeutic efficacy;
carcinoma
Journal Title: Hepatology Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!